News for Arvinas, Inc. (ARVN)

U.S. stocks traded lower midway through trading, with the Dow Jones falling more than 1% on Tuesday. The Dow traded down 1.07% to 41,462.06 while the NASDAQ de...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded ...

Massachusetts-based 2seventy bio, Inc. (TSVT), a cell and gene therapy company is up over 76 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Massachusetts-based 2seventy bio, Inc. (TSVT), a cell and gene therapy company is up over 76 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

On February 25, 2025, Pfizer Inc (Trades, Portfolio), a leading entity in the investment landscape, executed a noteworthy transaction involving Haleon PLC. The

Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Arvinas, Inc. ARVN reported worse-than-expected fourth-quarter sales results on Tuesday. Arvinas reported quarterly losses of 63 cents per share which beat the...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Revenue: $59.2 million in Q4 2024, compared to negative $43.1 million in Q4 2023; $263.4 million for the full year 2024, compared to $78.5 million in 2023.Gene

Earnings Call Insights: Arvinas, Inc. (NASDAQ:ARVN) Q4 2024Management ViewCEO John Houston emphasized that Arvinas is nearing key milestones, including the...

Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ETCompany ParticipantsJeff Boyle - Vice President of Investor...

Arvinas (ARVN) delivered earnings and revenue surprises of 41.12% and 4.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

ARVN is set to report Q4 earnings on February 11th. Consensus estimates show significant Y/Y growth in EPS and revenue.

Arvinas Inc (ARVN) is set to release its Q4 2024 earnings on Feb 11, 2025. The consensus estimate for Q4 2024 revenue is $65.28 million, and the earnings are ex

Summary Arvinas Inc (ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced a live webcast scheduled for Febr

NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. ( ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targe

On January 22, 2025, Opaleye Management Inc. (Trades, Portfolio) executed a substantial reduction in its holdings of Harrow Inc., a U.S.-based eyecare pharmaceu

Arvinas Inc (ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced significant updates and milestones for 20